68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
Fig 2
Kaplan–Meier survival curves for: (A) progression-free survival (PFS), (B) treatment failure-free survival (TFFS) (C) treatment failure-free survival by time from PCA diagnosis to first metastasis: >36 months vs ≤36 months, (D) local control (LC) by fractionation schedules: single fraction radiosurgery (SFRS) vs fractionated stereotactic body radiotherapy (fSBRT), (E) overall survival (OS), (F) overall survival by therapy initiated after progression: repeated SBRT (re-SBRT) vs other.